Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860135 | 0.87 | HPGD (0.50) | EPHX2NR1H4HTTKMT2ARAB9A | |
| SCHEMBL14859134 | 0.79 | NR1H4 (0.47) | NR1H4KMT2ARAB9AMEN1ATM | |
| SCHEMBL14859670 | 0.78 | ALDH1A1 (0.54) | HTTKMT2ARAB9ALMNAHPGD | |
| SCHEMBL14859532 | 0.77 | NR1H4 (0.50) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL14860316 | 0.77 | EPHX2 (0.59) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL14860245 | 0.76 | EPHX2 (0.54) | EPHX2NR1H4HTTKMT2ARAB9A | |
| SCHEMBL14859859 | 0.76 | ALDH1A1 (0.58) | EPHX2NR1H4HTTRIPK1KMT2A | |
| SCHEMBL14859225 | 0.76 | RAB9A (0.67) | EPHX2NR1H4RAB9ALMNA | |
| SCHEMBL14860301 | 0.76 | MEN1 (0.67) | EPHX2NR1H4KMT2ARAB9ALMNA | |
| SCHEMBL14859138 | 0.75 | NR1H4 (0.52) | EPHX2NR1H4HTTKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | EPHX2 2141/4885NR1H4 4314/4885HTT 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.